Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1580)	3/22/2006 2:13:07 PM
From: Jibacoa	Respond to of 3722

RGEN Came back from its early L and was almost able to trade at its March 17 H of 3.74 (was short by only a penny at 1.11PM) and it is now at 3.68. Will see if it can close above that level.<g> bigcharts.marketwatch.com If the stock can close above the resistance at $3.75 it may be an early indication that there could be a deal in the works with BMY. As I mentioned on my previous note to Peter, According to W.H., the FDA approved BMY's application for Orencia for RA treatment in December and in January RGEN & Michigan Univ. filed a complaint for infringement of US Patent No.6,685,941 which covers methods for using CTLA4-Ig for treating RA. He said that RGEN is seeking a royalty licensing agreement with BMY either by "litigation or negotiation". Message 22208878 With BMY & SNY agreement yesterday to settle a patent infringement lawsuit against Canada's Apotex over the multibillion-dollar anticoagulant Plavix, there is more speculation that BMY may be inclined to also settle with RGEN on its claim involving the Orencia patent claim. Bernard